

Literaturverzeichnis zum Titelthema

Psychiatrie und Psychotherapie heute

von Professor Dr. Peter Zwanzger und Dr. Niels-Christian Köstner

Bayerisches Ärzteblatt 1-2/2026, Seite 8 ff.

1. Baune BT, Fromme SE, Kiebs M, Hurlermann R. [Clinical management of treatment-resistant depression]. *Nervenarzt*. 2024;95(5):416-22.
2. Zilles D, Wolff-Menzler C, Wiltfang J. [Electroconvulsive therapy for the treatment of major depression]. *Nervenarzt*. 2015;86(5):549-56.
3. Vestring S, Domschke K, Normann C. [Ketamine and other N-methyl-D-aspartate receptor modulators in treatment of depression]. *Nervenarzt*. 2022;93(3):234-42.
4. Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. *N Engl J Med*. 2023;389(14):1298-309.
5. Zwanzger P, Meyding-Lamadé U. [Digital developments in neurology and psychiatry: digital health apps, telemedicine, AI-Blessing or threat?]. *Nervenarzt*. 2024;95(3):203-5.
6. Linardon J, Torous J, Firth J, Cuijpers P, Messer M, Fuller-Tyszkiewicz M. Current evidence on the efficacy of mental health smartphone apps for symptoms of depression and anxiety. A meta-analysis of 176 randomized controlled trials. *World Psychiatry*. 2024;23(1):139-49.
7. Kaminski J, Machleid F, Wiegmann C, Klein JP, Rakitzis O, Haaf R, et al. [Digital health applications for depressive disorders in Germany : A narrative review of the evidence and integration into treatment]. *Nervenarzt*. 2025;96(5):432-8.
8. Fenski F, Behr S, Schaeuffele C, Boettcher J, Knaevelsrud C. [Blended care: state of research and possibilities for implementation]. *Nervenarzt*. 2024;95(3):216-22.
9. Nationale Versorgungsleitlinie (NVL) Unipolare Depression - Langfassung, 2. Auflage
10. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. *Lancet Psychiatry*. 2024;11(7):526-35.